VYNE Therapeutics Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that VYNE Therapeutics Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $4.29M | Mar 4, 2021 |
| FY2020 | Sep 30, 2020 | $3.27M | Mar 4, 2021 |
| FY2020 | Jun 30, 2020 | $11.69M | Mar 4, 2021 |
| FY2020 | Mar 31, 2020 | $1.75M | Mar 4, 2021 |
| FY2020 | Dec 31, 2019 | $135.0K | Mar 4, 2021 |
| FY2020 | Sep 30, 2019 | $0 | Mar 4, 2021 |
| FY2020 | Jun 30, 2019 | $0 | Mar 4, 2021 |
| FY2020 | Mar 31, 2019 | $308.0K | Mar 4, 2021 |
| FY2018 | Dec 31, 2018 | $0 | Feb 28, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $570.0K | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $501.0K | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $424.0K | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $477.0K | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $931.0K | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $20.99M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $443.0K | Mar 4, 2021 |
| FY2020 | Dec 31, 2018 | $3.60M | Mar 4, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($26.48M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($39.83M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($28.45M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($23.21M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | ($73.33M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($255.57M) | Mar 17, 2022 |
| FY2019 | Dec 31, 2019 | ($21.50M) | Mar 3, 2020 |
| FY2019 | Sep 30, 2019 | ($16.86M) | Mar 3, 2020 |
| FY2019 | Jun 30, 2019 | ($16.48M) | Mar 3, 2020 |
| FY2019 | Mar 31, 2019 | ($18.87M) | Mar 3, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($29.75M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($43.64M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($29.26M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($34.30M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | ($38.91M) | Mar 14, 2023 |
| FY2020 | Dec 31, 2020 | ($21.99M) | Mar 4, 2021 |
| FY2020 | Sep 30, 2020 | ($23.49M) | Mar 4, 2021 |
| FY2020 | Jun 30, 2020 | ($167.18M) | Mar 4, 2021 |
| FY2020 | Mar 31, 2020 | ($39.89M) | Mar 4, 2021 |
| FY2020 | Dec 31, 2019 | ($37.43M) | Mar 4, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.24M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $30.95M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $16.31M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $18.39M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $19.54M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $43.53M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $51.20M | Mar 4, 2021 |
| FY2020 | Dec 31, 2018 | $64.47M | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $29.01M | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | $11.26M | Feb 28, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $16.39M | Mar 14, 2023 |
| FY2022 | Dec 31, 2021 | $20.30M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $89.54M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $45.11M | Mar 4, 2021 |
| FY2020 | Dec 31, 2018 | $14.01M | Mar 4, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($33.12M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($33.97M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($25.34M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($29.20M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | ($56.37M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($137.08M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($73.39M) | Mar 4, 2021 |
| FY2020 | Dec 31, 2018 | ($68.66M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | ($28.22M) | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | ($2.27M) | Feb 28, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $0 | Mar 17, 2022 |
| FY2021 | Dec 31, 2020 | $113.0K | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $1.06M | Mar 4, 2021 |
| FY2020 | Dec 31, 2018 | $567.0K | Mar 4, 2021 |
| FY2019 | Dec 31, 2017 | $27.0K | Mar 3, 2020 |
| FY2018 | Dec 31, 2016 | $31.0K | Feb 28, 2019 |
| FY2017 | Dec 31, 2015 | $0 | Mar 28, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.16M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $66.91M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $97.69M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $40.76M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $67.05M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $93.74M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $81.16M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $139.93M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $66.87M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $42.05M | Mar 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.40M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $14.82M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $8.95M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $9.35M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $18.41M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $56.25M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $63.58M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | $9.55M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $14.57M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | $12.49M | Mar 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.77M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $52.09M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $88.74M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $31.20M | Mar 6, 2025 |
| FY2023 | Dec 31, 2021 | $48.64M | Mar 1, 2024 |
| FY2022 | Dec 31, 2020 | $37.49M | Mar 14, 2023 |
| FY2021 | Dec 31, 2019 | $17.58M | Mar 17, 2022 |
| FY2020 | Dec 31, 2018 | $92.18M | Mar 4, 2021 |
| FY2020 | Dec 31, 2017 | $68.60M | Mar 4, 2021 |
| FY2019 | Dec 31, 2016 | ($29.44M) | Mar 3, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($757.65M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($731.17M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($691.34M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($662.74M) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | ($639.53M) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | ($566.20M) | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | ($310.59M) | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | ($110.64M) | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | ($59.19M) | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | ($30.12M) | Mar 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.03M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $19.93M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $30.62M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $30.91M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | $42.25M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | $57.56M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | $43.76M | Mar 4, 2021 |
| FY2020 | Dec 31, 2018 | $27.87M | Mar 4, 2021 |
| FY2018 | Dec 31, 2017 | $10.21M | Feb 28, 2019 |
| FY2018 | Dec 31, 2016 | $4.03M | Feb 28, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2024 | $0 | Mar 6, 2025 |
| FY2023 | Dec 31, 2023 | $0 | Mar 1, 2024 |
| FY2022 | Dec 31, 2022 | $0 | Mar 14, 2023 |
| FY2021 | Dec 31, 2021 | $0 | Mar 17, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | (7) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | (25) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 7 | Mar 17, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | (7) | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | (25) | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 7 | Mar 17, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 33.32M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 14.83M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 14.10M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 3.23M | Mar 1, 2024 |
| FY2022 | Dec 31, 2021 | 2.98M | Mar 14, 2023 |
| FY2021 | Dec 31, 2020 | 43.21M | Mar 17, 2022 |
| FY2020 | Dec 31, 2019 | 9.12M | Mar 4, 2021 |
| FY2019 | Dec 31, 2018 | 23.23M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | 5.30M | Feb 28, 2019 |
| FY2017 | Dec 31, 2016 | 5.28M | Mar 28, 2018 |